Method for achieving desired glial growth factor 2 plasma levels
AssigneeAcorda Therapeutics, Inc.
InventorsHaesun Kim, Anthony O. Caggiano
Life of this patent
Estimating the term…
Abstract
The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
Claims10
A method for avoiding inhibition of Schwann cell myelination following administration of glial growth factor 2 (GGF2) in a subject, said method comprising:
- administering an amount of GGF2 to the subject;
- sufficient to elicit a plasma level of between about 0.0005 and about 0.01 nM GGF2.
A method for avoiding inhibition of Schwann cell myelination following administration of glial growth factor 2 (GGF2) in a subject, said method comprising administering about 500 ng of GGF2 per kg of body weight.
A method for promoting myelination in a patient afflicted with a disease or disorder associated with reduced levels of myelination, the method comprising:
- selecting the patient afflicted with a disease or disorder associated with reduced levels of myelination;
- administering glial growth factor 2 (GGF2) to the patient in an amount of about 500 ng of GGF2 per kg of body weight;
- whereby myelination is promoted.
A method for promoting myelination in a patient afflicted with a disease or disorder associated with reduced levels of myelination, the method comprising:
- selecting a patient afflicted with a disease or disorder associated with reduced levels of myelination;
- and,
- administering glial growth factor 2 (GGF2) to the patient at an amount that achieves a plasma level of between about 0.0005 and about 0.01 nM GGF2.
Dependencies are inferred from the claim text.